对1例免疫治疗期间发生结肠炎的肝癌患者的药物治疗管理

Drug therapy for a patient with liver cancer complicating with colitis during immunotherapy

免疫治疗已成为肝癌系统治疗的重要组成部分,能进一步提高肿瘤治疗预后,但由此产生的免疫相关不良反应(irAEs)正成为困扰临床用药的棘手问题。本文报道了1例肝癌患者,在应用特瑞普利单抗联合仑伐替尼治疗期间出现免疫相关结肠炎。临床药师通过查阅文献,逐个分析药物,有效参与到患者停药、治疗及重启的药物治疗管理中。

Immunotherapies are an important part of systemic therapies for liver cancer,to improve the prognosis of tumor treatment.However,clinicians hesitate to use these drugs due to immunerelated adverse events.This paper reported a case of severe immune-related colitis in a patient with liver cancer during the treatment of toripalimab combined with lenvatinib.By searching literature and analyzing each drug,clinical pharmacists effectively involved in the therapy management on drug discontinuation and resumption.